{"created":"2023-05-15T15:02:46.449304+00:00","id":85108,"links":{},"metadata":{"_buckets":{"deposit":"23c04940-08af-425c-985b-19ee9473853c"},"_deposit":{"created_by":1,"id":"85108","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"85108"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00085108","sets":["1"]},"author_link":["1026125","1026119","1026108","1026114","1026111","1026128","1026112","1026116","1026124","1026126","1026120","1026123","1026109","1026121","1026110","1026127","1026122","1026113","1026115","1026118","1026117"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"67","bibliographicVolumeNumber":"14","bibliographic_titles":[{"bibliographic_title":"Pharmaceutics"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: Early diagnosis of pancreatic cancer using current imaging modalities remains challenging. We have developed a new approach to identify the tumor lesions ≥ 3 mm in the pancreas by positron emission tomography (PET) with intraperitoneally administered 64Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Generally, in clinical research, radiometal-antibody complex must be prepared immediately before use at imaging site. To make 64Cu-NCAB001 ipPET become available to daily clinical practices sustainably, the NCAB001-chelator conjugate and 64Cu-NCAB001 must be characterized and stabilized. Methods: NCAB001 was manufactured under cGMP conditions. The conjugation of NCAB001 with bifunctional chelator (p-SCN-Bn-PCTA) was conducted, and the antibody-chelator conjugate (PCTA-NCAB001) was characterized by LC/MS and ELISA. Thereafter, to manufacture 64Cu-NCAB001 effectively, we developed a new formulation to stabilize the PCTA-NCAB001 and 64Cu-NCAB001. Results. An average of three PCTA chelators were conjugated per molecule of NCAB001. The relative binding potency of PCTA-NCAB001 was comparable to cetuximab. The formulation consisting of acetate buffer, glycine, and polysorbate-80 stabilized the PCTA-NCAB001 for a year-long storage. Additionally, this formulation enabled the stabilization of 64Cu-NCAB001 for up to 24 h after radiolabeling with sufficient radioactivity concentration for clinical use. Conclusion: These results may accelerate the future use of 64Cu-NCAB001 ipPET in the clinical settings for the early diagnosis and treatment of pancreatic cancer.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/pharmaceutics14010067","subitem_relation_type_select":"DOI"}}]},"item_8_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.mdpi.com/1999-4923/14/1/67","subitem_relation_type_select":"URI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1999-4923","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hiroki, Matsumoto"}],"nameIdentifiers":[{"nameIdentifier":"1026108","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chika, Igarashi"}],"nameIdentifiers":[{"nameIdentifier":"1026109","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tomoko, Tachibana"}],"nameIdentifiers":[{"nameIdentifier":"1026110","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fukiko, Hihara"}],"nameIdentifiers":[{"nameIdentifier":"1026111","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsuo, Waki"}],"nameIdentifiers":[{"nameIdentifier":"1026112","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong"}],"nameIdentifiers":[{"nameIdentifier":"1026113","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sei, Yoshida"}],"nameIdentifiers":[{"nameIdentifier":"1026114","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kenichiro, Naito"}],"nameIdentifiers":[{"nameIdentifier":"1026115","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hiroaki, Kurihara"}],"nameIdentifiers":[{"nameIdentifier":"1026116","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Makoto, Ueno"}],"nameIdentifiers":[{"nameIdentifier":"1026117","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kimiteru, Ito"}],"nameIdentifiers":[{"nameIdentifier":"1026118","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsuya, Higashi"}],"nameIdentifiers":[{"nameIdentifier":"1026119","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yukie, Yoshii"}],"nameIdentifiers":[{"nameIdentifier":"1026120","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hiroki, Matsumoto","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026121","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chika, Igarashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026122","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tomoko, Tachibana","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026123","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fukiko, Hihara","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026124","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsuo, Waki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026125","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026126","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsuya, Higashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026127","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yukie, Yoshii","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026128","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-12-28"},"publish_date":"2021-12-28","publish_status":"0","recid":"85108","relation_version_is_last":true,"title":["Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T18:00:00.949721+00:00"}